Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under Reg 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Zydus Lifesciences Ltd - 532321 - Dissolution Of A Wholly Owned Subsidiary
Dissolution of a wholly owned subsidiary Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives approval from USFDA to initiate Phase II clinical trial of ZYIL1 in patients with Parkinson''s disease. Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Lacosamide Tablets. Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Darunavir Tablets 600 mg and 800 mg and tentative approval for 75 mg and 150 mg Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Cyclophosphamide Capsules USP, 25 mg and 50 mg Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of share certificate Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus and Daewoong Pharmaceuticals announce exclusive licensing agreement for development and commercialization of Leuprolide Long-Acting Injectable in the U.S.